Shoshana Rath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shoshana Rath has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Adrian K. Charles
Department of Paediatric and Perinatal Pathology, PathWest, Perth Children's Hospital, Nedlands, WA, Australia
1 shared publication Anthony Bartley
Diagnostic Imaging (A.B., N.P.), Princess Margaret Hospital for Children, Perth, WA 6008, Australia
1 shared publicationCatherine S. Y. Choong
Department of Endocrinology and Diabetes (S.R.R., T.J., C.S.Y.C.), Princess Margaret Hospital for Children, Perth, WA 6008, Australia
1 shared publicationCatherine Sy Choong
Department of Endocrinology and Diabetes Princess Margaret Hospital for Children Perth Western Australia Australia
1 shared publicationCathy Choong
Department of Endocrinology Princess Margaret Hospital , Child and Adolescent Services & School of Pediatrics and Child Health, University of Western Australia Perth Australia
1 shared publicationGareth Baynam
School of Pediatrics and Child Health (S.R.R., G.B., T.J., C.S.Y.C.), University of Western Australia, Perth, WA 6008, Australia
1 shared publication
Latest Publications
- Open Access
- 14 October 2014
- Published by Bioscientifica in Endocrine Abstracts
cDNA analysis reveals NNT pseudoexon activation in two siblings with familial glucocorticoid deficiency
Aberrant pseudoexon inclusion is rarely recognised as a cause of human disease. Here we report two novel, compound heterozygous mutations in nicotinamide nucleotide transhydrogenase (NNT), one of which activates a pseudoexon, as the cause of familial glucocorticoid deficiency in two siblings. Whole-exome sequencing identified a single novel, heterozygous variant (R71X) in both affected individuals. Follow-up cDNA analysis identified the pseudoexon inclusion (p.P998_D999ins23) and Sanger sequencing of genomic DNA identified a 4 bp duplication responsible for its’ activation. The variants segregated with the disease, R71X was inherited from the mother, P998_D999ins23 from the father and an unaffected sibling had inherited only the R71X variant. Neither variant has been annotated in any SNP or mutation databases and both will lead to premature truncation and presumably an inactive protein. The mutation resulting in pseudoexon inclusion could provide a potential target for antisense oligonucleotide therapy. Detection of such events in disease is hampered since introns, because of their frequently large size, are often excluded from mutational analyses, and it is often impossible/impractical to perform cDNA analysis.
- 14 October 2014
- Published by Bioscientifica in Endocrine Abstracts
Open AccesscDNA analysis reveals NNT pseudoexon activation in two siblings with familial glucocorticoid deficiency
Aberrant pseudoexon inclusion is rarely recognised as a cause of human disease. Here we report two novel, compound heterozygous mutations in nicotinamide nucleotide transhydrogenase (NNT), one of which activates a pseudoexon, as the cause of familial glucocorticoid deficiency in two siblings. Whole-exome sequencing identified a single novel, heterozygous variant (R71X) in both affected individuals. Follow-up cDNA analysis identified the pseudoexon inclusion (p.P998_D999ins23) and Sanger sequencing of genomic DNA identified a 4 bp duplication responsible for its’ activation. The variants segregated with the disease, R71X was inherited from the mother, P998_D999ins23 from the father and an unaffected sibling had inherited only the R71X variant. Neither variant has been annotated in any SNP or mutation databases and both will lead to premature truncation and presumably an inactive protein. The mutation resulting in pseudoexon inclusion could provide a potential target for antisense oligonucleotide therapy. Detection of such events in disease is hampered since introns, because of their frequently large size, are often excluded from mutational analyses, and it is often impossible/impractical to perform cDNA analysis.
- Open Access
- 1 June 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (6) , 1947-1948
Multinodular Goiter in Children: An Important Pointer to a Germline DICER1 Mutation
Disclosure Summary: The authors have nothing to disclose.
- 1 June 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (6) , 1947-1948
Open AccessMultinodular Goiter in Children: An Important Pointer to a Germline DICER1 Mutation
Disclosure Summary: The authors have nothing to disclose.
- 5 April 2013
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 49 (5) , 403-408
Childhood craniopharyngioma: 20‐year institutional experience in Western Australia
Aim: A retrospective audit was undertaken to evaluate modes of presentation and treatment outcomes for craniopharyngioma in a single paediatric institution over a 20‐year period.Methods: A search of the neurosurgical and histopathological databases for patients under 21 years of age treated for craniopharyngioma between 1990 and 2010 was performed at our institution. The clinical records of eligible patients were reviewed and information regarding presentation, medical and surgical management and post‐treatment outcome were extracted and collated.Results: Of 10 evaluable patients, the commonest presenting symptoms were headache and visual impairment. Clinical and biochemical evaluation undertaken prior to surgery revealed visual dysfunction in 70% and pituitary deficit in 30%. Gross total resection was achieved in 40% but was curative in only 20%. The remaining 80% required further surgical and/or radiotherapeutic intervention. Seven patients had radiation therapy with stabilisation in 70%. Multiple Pituitary Hormone Deficiency evolved in all patients over time, while visual impairment worsened in 30% post‐operatively and improved in 20%. Obesity was present in 50% after a mean follow‐up interval of 5.6 years and was apparent within 1 year of initial surgery in 30%. Although neurocognitive, psychological and behavioural problems were noted for some patients during medical review, only 20% of patients were formally assessed.Conclusions: Craniopharyngioma is associated with significant long‐term morbidity. Attention to an integrated care pathway that includes standardised neurocognitive and psychological and behavioural assessment would facilitate early appropriate intervention and support leading to an improved quality of life for children with craniopharyngioma.
- 5 April 2013
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 49 (5) , 403-408
Childhood craniopharyngioma: 20‐year institutional experience in Western Australia
Aim: A retrospective audit was undertaken to evaluate modes of presentation and treatment outcomes for craniopharyngioma in a single paediatric institution over a 20‐year period.Methods: A search of the neurosurgical and histopathological databases for patients under 21 years of age treated for craniopharyngioma between 1990 and 2010 was performed at our institution. The clinical records of eligible patients were reviewed and information regarding presentation, medical and surgical management and post‐treatment outcome were extracted and collated.Results: Of 10 evaluable patients, the commonest presenting symptoms were headache and visual impairment. Clinical and biochemical evaluation undertaken prior to surgery revealed visual dysfunction in 70% and pituitary deficit in 30%. Gross total resection was achieved in 40% but was curative in only 20%. The remaining 80% required further surgical and/or radiotherapeutic intervention. Seven patients had radiation therapy with stabilisation in 70%. Multiple Pituitary Hormone Deficiency evolved in all patients over time, while visual impairment worsened in 30% post‐operatively and improved in 20%. Obesity was present in 50% after a mean follow‐up interval of 5.6 years and was apparent within 1 year of initial surgery in 30%. Although neurocognitive, psychological and behavioural problems were noted for some patients during medical review, only 20% of patients were formally assessed.Conclusions: Craniopharyngioma is associated with significant long‐term morbidity. Attention to an integrated care pathway that includes standardised neurocognitive and psychological and behavioural assessment would facilitate early appropriate intervention and support leading to an improved quality of life for children with craniopharyngioma.
- 28 June 2008
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 44 (6) , 383-384
Octreotide in children with hypoglycaemia due to sulfonylurea ingestion
Abstract: Sulfonylureas are commonly prescribed for type 2 diabetes mellitus; however, overdose or accidental ingestion may result in profound and prolonged hypoglycaemia with permanent neurological sequelae and death. We describe two cases of children with hypoglycaemia due to presumed accidental ingestion of sulfonylureas, where traditional methods of raising blood sugar levels were unsatisfactory. Two studies describe Octreotide for adults with hypoglycaemia, but there are no studies examining the use of Octreotide in children for this indication. Given that Octreotide has been shown to be safe in children when used for other indications, we used Octreotide to safely restore euglycaemia.
- 28 June 2008
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 44 (6) , 383-384
Octreotide in children with hypoglycaemia due to sulfonylurea ingestion
Abstract: Sulfonylureas are commonly prescribed for type 2 diabetes mellitus; however, overdose or accidental ingestion may result in profound and prolonged hypoglycaemia with permanent neurological sequelae and death. We describe two cases of children with hypoglycaemia due to presumed accidental ingestion of sulfonylureas, where traditional methods of raising blood sugar levels were unsatisfactory. Two studies describe Octreotide for adults with hypoglycaemia, but there are no studies examining the use of Octreotide in children for this indication. Given that Octreotide has been shown to be safe in children when used for other indications, we used Octreotide to safely restore euglycaemia.